Abbvie Stock News

Abbvie Inc''s (NYSE: ABBV ) short percent of float has risen 3.9% since last its last report. The company recently reported that it has 14.09 million shares sold short , which is 0.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.0 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling Full story available on Benzinga.com

There''s still a worst-case scenario that the FDA could unleash.

Related Stocks: INTU , MSFT , ABBV , CTSH , CAT , VMW , PM , USB , MMC , APD , TXN , CFG , CRM , TJX , TMO , AON , NOC , COST ,

Signaturefd LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 1.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,748 shares of the companys stock after selling 317 shares during the quarter. Signaturefd LLCs holdings in AbbVie were worth $3,425,000 at the end []

Suresh Pattathil, MD & GM, Allergan AbbVie updates Viveka Roychowdhury on the operational and cultural integration of Allergan into AbbVie in a virtual environment on a global basis midst a pandemic, the merged entitys focus in India and how continuous patient education and awareness resulted in steady resumption of treatment and surgeries in eye care The post Allergan AbbVie in India to continue high focus on eyecare, neurosciences and aesthetics appeared first on Express Pharma .

Navellier & Associates Inc. lessened its position in AbbVie Inc. (NYSE:ABBV) by 1.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 25,589 shares of the companys stock after selling 472 shares during the period. Navellier & Associates Inc.s holdings in AbbVie were worth $2,760,000 at the end []

Texas Permanent School Fund decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 7.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 272,998 shares of the companys stock after selling 20,420 shares during the quarter. Texas Permanent School Funds holdings in AbbVie were []

IRVINE, Calif., Dec. 16, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the successful completion of its acquisition of Soliton, Inc. (NASDAQ: SOLY). The addition of Soliton and its technology complements Allergan

Dublin, Dec. 16, 2021 (GLOBE NEWSWIRE) -- The "Biotech Ingredients Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com''s offering. The global biotech ingredients market exhibited moderate growth during 2015-2020. Looking forward, the publisher expects the market to grow at a CAGR of 8.6% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use industries. These insights are included in the report as a major market contributor. Biotech ingredients are prepared using organisms like algae, yeast or bacteria that undergo deoxyribonucleic acid (DNA) editing to enhance the metabolic process of microbes. They are cost-effective and generate a low environmental impact than ingredients processed using petrochemicals. They act as a sustainable alternative to formulate plant-based extracts, which can counteract oxidative damages and slow down the aging process.

Morris Retirement Advisors LLC increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 6.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,275 shares of the companys stock after buying an additional 383 shares during the period. Morris Retirement Advisors []

Manchester Financial Inc. lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 4.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,517 shares of the companys stock after buying an additional 298 shares during the period. Manchester Financial Inc.s []

American Research & Management Co. reduced its position in AbbVie Inc. (NYSE:ABBV) by 6.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 2,911 shares of the companys stock after selling 200 shares during the period. American Research & Management Co.s holdings in AbbVie were worth $314,000 at []

When Idera Pharmaceuticals flunked a Phase III melanoma trial with its Toll-like receptor 9 agonist tilsotolimod back in March, executives clung to the hope that separate trials in other cancers would turn up better results. Without the results it was hoping for, Idera says its now discontinuing enrollment in a

Clean Yield Group grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 25.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,967 shares of the companys stock after purchasing an additional 817 shares during the period. Clean Yield Groups holdings in AbbVie were worth []

Ziegler Capital Management LLC lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 13.0% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 91,316 shares of the companys stock after selling 13,613 shares during the quarter. Ziegler Capital Management LLCs holdings in AbbVie []